GSK has reported a 7% increase in full-year revenue for 2024, reaching £31.4 billion ($39.3 billion), slightly surpassing market expectations. The fourth quarter contributed £8.1 billion, a 4% rise ...

Shares of GSK plc (NYSE:GSK – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are covering the stock, Marketbeat reports. Six ...

Final investment decisions had been made for the Tarbert Next (LON: NXT) Generation biopower station in Co Kerry and the ...

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

Johnson & Johnson (NYSE: JNJ) has gone big early doors this year in the world of pharma M&A. The US healthcare giant ...

Ballentine Partners LLC boosted its holdings in shares of GSK plc (NYSE:GSK – Free Report) by 40.7% in the fourth quarter, ...

The Mayor of London has launched a new nightlife taskforce which will be led by fabric nightclub founder Cameron Leslie - it will be advising on the future of nightlife in the capital ...

Nitin Sahney, co-founder and CEO of PharmaCord, poses for a portrait in the pharmaceutical support company’s new headquarters ...

Does social media bring commercial benefits to GSK? That's not exactly the point, according to Quayle and Morgan. "Increasing sales is not one of our KPIs", says Morgan, "although building ...

“We really became impressed with what IDRx had achieved,” GSK Chief Commercial Officer Luke Miels told Fierce Biotech in an interview ahead of the J.P. Morgan Healthcare Conference.